Table 5.

Logistic regression models

	Psoriatic arthritis in remission
	Odds ratio	SE	95% CI	p value
Model 1
PsA acceptable disease activity	17.13	4.50	10.24–28.68	< 0.0001
Model 2
PsA acceptable disease activity	3.56	1.17	1.86–6.80	< 0.0001
PsA Global QoL	0.55	0.40	0.48–0.64	< 0.0001
Model 3
PsA acceptable disease activity	4.68	2.04	1.99–11.00	< 0.0001
PsA Global QoL	0.58	0.05	0.48–0.70	< 0.0001
Psoriasis in remission	7.07	2.78	3.27–15.27	< 0.0001
Model 4
PsA acceptable disease activity	4.70	2.10	1.96–11.24	0.01
PsA Global QoL	0.57	0.05	0.47–0.69	< 0.0001
Psoriasis in remission	6.80	2.68	3.14–14.74	< 0.0001
White	0.28	0.17	0.08–0.92	0.05
Model 5
PsA acceptable disease activity	5.10	2.74	1.78–14.61	0.01
PsA Global QoL	0.54	0.06	0.43–0.69	< 0.0001
Psoriasis in remission	4.84	2.18	2.00–11.69	< 0.0001
White	0.28	0.18	0.08–1.00	0.051
Multiple therapy use	0.62	0.24	0.28–1.34	0.225
Obese/overweight	1.06	0.47	0.45–2.52	0.888
Male	0.78	0.33	0.34–1.78	0.561
Biologic user	0.97	0.50	0.35–2.69	0.953
Model 6
PsA acceptable disease activity	4.58	2.51	1.56–13.43	0.01
PsA Global QoL	0.55	0.06	0.43–0.69	< 0.0001
Psoriasis in remission	4.51	2.05	1.84–11.02	0.01
White	0.28	0.18	0.08–1.00	0.05
Multiple therapy use	0.61	0.24	0.28–1.33	0.215
Obese/overweight	1.04	0.46	0.44–2.46	0.935
Male	0.82	0.36	0.35–1.93	0.665
Biologic user	0.91	0.48	0.32–2.57	0.853
Age	0.99	0.01	0.96–1.02	0.725
Number of comorbidities	1.05	0.09	0.88–1.25	0.567